Argenx Se (ARGX) Gains from Investment Securities (2020 - 2021)
Argenx Se (ARGX) posted Gains from Investment Securities of $11.2 million for Q1 2021, up 358.38% on a QoQ basis from -$4.3 million in Q4 2020.
Argenx Se (ARGX) Gains from Investment Securities (2020 - 2021) Analysis & Trends
Argenx Se's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $11.2 million for Q1 2021.
- Quarterly Gains from Investment Securities changed N/A year-over-year to $11.2 million in Q1 2021, while the trailing twelve-month figure through Jun 2021 was $7.1 million (changed N/A YoY) and the FY2025 annual result came in at -$11.6 million, down 202.06% from the prior year.
- Gains from Investment Securities was $11.2 million for Q1 2021 at Argenx Se, up from -$4.3 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $11.2 million in Q1 2021 and bottomed at -$4.3 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 11.15 Mn |
| Mar 31, 2021 | 11.15 Mn |
| Dec 31, 2020 | -4.32 Mn |
| Dec 31, 2020 | -4.32 Mn |
| Sep 30, 2020 | 266,321.61 |
| Sep 30, 2020 | 266,321.61 |
| Jun 30, 2020 | 934,000.00 |
| Jun 30, 2020 | 934,000.00 |